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ABSTRACT 
Human melanoma is one of the deadliest forms of cancer, with poor prognosis and high 
resistance to chemotherapy and radiotherapy. The discovery of immunosuppressive 
mechanisms in the human melanoma microenvironment led to the use of new prognostic 
markers and to the development of immunotherapies targeting immune checkpoint 
molecules. Immunoescape mechanisms in canine melanoma have not yet been 
investigated and no such immunotherapy has been tested.  
The aim of this study was to provide preliminary data on the expression of FoxP3 and IDO 
in primary canine melanocytic tumors and to investigate their prognostic role. 
Formalin-fixed, paraffin-embedded (FFPE) samples from 74 canine melanocytic tumors 
(26 oral melanomas, 23 cutaneous melanomas and 25 cutaneous melanocytomas) were 
retrospectively evaluated by immunohistochemistry to explore the expression of FoxP3 
and IDO. 
An increased risk of death due to melanoma was associated with a higher number of 
FoxP3+ cells per high-power field (FoxP3+/HPF), a higher percentage of CD3+ cells that 
were also FoxP3+ infiltrating and surrounding the tumor (%FoxP3), and a higher number of 
IDO+ cells/HPF (IDO+/HPF). A prognostic value for FoxP3 and IDO is suggested by our 
study, with optimal cut-offs of 14.7 FoxP3+ cells/HPF, 6.1 IDO+ cells/HPF and 12.5% 
FoxP3+ cells. Both markers were also associated with tumor type. Multivariable analysis 
identified IDO+/HPF (P<0.001) as an independent prognostic marker. Even though 
stratification by diagnosis caused a loss of significance, results from the present study 
suggest a prognostic role for IDO and FoxP3, possibly related to the establishment of an 
immunosuppressive microenvironment. 
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Although melanoma accounts for only 5% of human cutaneous tumors, it represents the 
deadliest form of skin cancer, being difficult to treat and resistant to common therapies 
such as chemotherapy and radiotherapy.27,49,53 Oral human melanoma occurs rarely and 
also has a poor prognosis.14 Melanocytic tumors in dogs are common, since melanoma 
represents 7% of all malignancies diagnosed;39,63 canine oral melanoma is particularly 
aggressive, scarcely responsive to conventional therapies and associated with a poor 
prognosis.4,1 On the other hand, cutaneous melanocytic neoplasms display a less 
aggressive behavior, and surgical excision is usually curative.50 In the last few years, the 
characterization of the immune microenvironment has been considered critical for 
assessing the prognosis and predicting the response to therapy in human 
melanoma.30,56,25,26,37,2,13 In contrast, in canine melanoma,62,64 the role, the characteristics 
and the potential prognostic value of immune microenvironment profiling is still largely 
unexplored.1 
The capability of tumor cells to escape from immune destruction has been classified as 
one of the emerging hallmarks of cancer, confirming the pivotal role of the immune system 
in the control of tumor formation and progression.22 The interaction between the immune 
system and tumor progression has been best described by the process of 
“immunoediting”, which consists of three phases: elimination, as cancer cells are 
destroyed by the immune system; equilibrium, when the tumor enters a dynamic balance 
with the immune system; and escape, with the establishment of peripheral tolerance and 
of an immunosuppressive microenvironment.12,29,42,69 
Current knowledge on the immunology of human melanoma postulates that in the 
melanoma microenvironment, different systems of immunoescape can be activated to 
reduce the capability of cytotoxic (CD8+) T cells to destroy tumor cells.29 Among these 
systems is the production of immunosuppressive factors, including transcription factor 
forkhead box protein P3 (FoxP3) and indoleamine 2,3-dioxygenase (IDO). 
FoxP3 is a pivotal intracellular molecule for the development of Tregs, an 
immunoregulatory subset of CD4+ T cells.70 Tregs are divided into different subgroups: the 
two major subsets are naïve Tregs (nTregs), which develop in the thymus and contribute 
to maintaining peripheral tolerance, and inducible Tregs (iTregs), which are induced at the 
periphery, and mediate suppression by producing TGF-β and IL-10.70,18 FoxP3 is the most 
reliable Treg marker so far, even though this molecule can be transiently induced in non-
Treg cells, including cancer cells.34,72,16,33,51 Tregs suppress the activation and function of 
other leukocytes, including CD4+ and CD8+ T cells, B cells and antigen presenting cells 
(APCs) such as dendritic cells (DCs).18 In the last few years, growing evidence sheds 
some light on anti-tumor immune response, where Tregs seem to act in order to maintain 
an immunological tolerance in host tissues.34,61,33 Recently, different studies focused on 
the role of FoxP3+ Tregs in cancer and in melanoma, suggesting their role in 
immunosuppression and in cancer resistance to immunotherapy.46 The usefulness of 
FoxP3 as a prognostic factor in cancer is still controversial, but different studies highlighted 
a negative prognostic role of FoxP3+ Tregs in cancer including melanoma.17,31,55,61 In 
human medicine, a link between melanoma malignant behavior and the presence of 
FoxP3+ Tregs has been observed,16,40,44,51 whereas data in dogs are still limited.24,59,68 
Indoleamine 2,3-dioxygenase (IDO, also called IDO1) is a cytosolic enzyme involved in the 
acquisition of peripheral tolerance.46 It is constitutively expressed in different mammalian 
tissues, including the epididymis, placenta, spleen, thymus, lung and digestive tract.11 IDO 
can be expressed by APCs (macrophages and DCs), epithelial cells, vascular endothelium 
and cancer cells. This molecule is involved in the catabolism of tryptophan (TRP) to 
kynurenine (KYN) and KYN-pathway metabolites. The depletion of TRP is recognized as a 
mechanism of immunoregulation, because its metabolites suppress T-cell function and 
antitumor immune response by decreasing the immunogenicity of DCs and promoting 
differentiation of FoxP3+ Tregs. FoxP3+ Tregs can, in turn, promote IDO activation.23,47,48,46 
The expression of the enzyme IDO has been reported in different human cancers and has 
usually been associated with a worse prognosis. Different studies aimed at the evaluation 
of IDO as a prognostic marker in human melanoma have pointed out an association 
between IDO expression and a poorer prognosis (clinical recurrence and/or shorter overall 
survival) both in primary melanoma, lymph nodes and metastases.56,9,32,57,52,8,65 IDO 
activity has been hypothesized to play a role in different stages of tumor development, 
being expressed both very early in melanoma development, as well as in blood and 
metastatic tissue of patients years after surgery. It has been recently shown that the use of 
IDO-inhibitors in melanoma patients can enhance tumor immunity and improve 
chemotherapy response, although recent clinical trials have shown that better results can 
be obtained when IDO inhibition is combined with either chemotherapy or other 
immunotherapeutic strategies.7 
The aim of this study was to characterize FoxP3 and IDO expression in primary canine 
melanocytic tumors and to investigate their potential use as prognostic markers. 
 
MATERIALS AND METHODS 
Sample selection and histological evaluation 
Seventy-four formalin-fixed, paraffin-embedded (FFPE) samples of canine primary 
melanocytic tumors were selected from the archives of the Department of Veterinary 
Medicine at University of Perugia and of the Department of Veterinary Science at 
University of Torino (Italy). All samples were collected by clinicians and submitted for 
histological diagnosis between 2009 and 2016. 
The amelanotic tumors were included in the study only if positivity for either Melan-A or 
PNL-2 was demonstrated. Since there was only one tumor classified as oral 
melanocytoma, it was excluded from the statistics, but it was submitted for 
immunohistochemistry for descriptive purposes.  
The final study population included 26 oral melanomas, 23 cutaneous melanomas and 25 
cutaneous melanocytomas. Samples were re-examined by a boarded pathologist (CB) to 
confirm the diagnosis. Mitotic count was recorded.38 The presence of metastases was 
histologically assessed if original submission included regional lymph nodes and/or distant 
organs. Referring veterinarians were asked about the tumor staging (TNM), follow-up, 
local recurrence and the cause of death. Presence or absence of metastases at time of 
diagnosis was recorded based on feedback from referring veterinarians. 
 
Immunohistochemistry 
Samples were cut into slices of 5 μm and mounted on poly-L-lysine coated slides, 
dewaxed and rehydrated. Heavily pigmented tumors were bleached overnight at room 
temperature with 30% H2O2, following a modified protocol.36 In a preliminary experiment, 
we performed bleaching before and after the application of the primary antibodies and 
found no effect on the immunohistochemical results. Therefore, for practical reasons, we 
decided to use the pre-IHC bleaching protocol. Immunohistochemistry was performed on 
serial sections following standard protocols6 with antibodies against CD3 (rabbit 
polyclonal; 1:200; A 0452; Dako, Glostrup, Denmark), FoxP3 (rat monoclonal; 1:100; 
Clone FJK-16s; Thermo Fisher, Waltham, Massachusetts,US) and IDO (rabbit polyclonal; 
1:50; Biorbyt, Cambridge, UK). Heat-induced epitope retrieval was performed in a 
microwave for 20’ in TRIS-EDTA buffer (pH 9.0). After incubation with primary antibodies 
(2 hours for IDO and CD3 and overnight for FoxP3), slides for IDO and CD3 
immunolabeling were treated with an ABC ready-to-use kit (Abcam, Cambridge, UK) 
following manufacturer’s instructions. For FoxP3 immunolabeling, a rat biotinylated 
secondary antibody was incubated after the primary antibody and then streptavidin was 
applied. Positive reaction was revealed with 3-amino-9-ethilcarbazole (Dako, Glostrup, 
Denmark) and Mayer’s hematoxylin was applied as a counterstain. Reactive canine lymph 
node was used as a positive control for all antibodies of this study. Negative controls were 
incubated with TBS, omitting the primary antibody.  
 
Evaluation of FoxP3 and IDO expression 
The number of FoxP3+ nuclei of cells interpreted as lymphocytes was counted in 5 HPF 
(FN20), selecting “hot spots” and avoiding areas near necrosis or ulceration; the mean 
value was then calculated. The amount of infiltrating and peripheral CD3+ lymphocytes 
was given a semi-quantitative evaluation considering the whole section (occasional 
lymphocytes scattered in the mass = mild; moderate number of lymphocytes admixed with 
neoplastic cells = moderate; numerous lymphocytes, sometimes arranged in aggregates = 
severe). Two operators independently quantified the percentage of FoxP3+ cells in the 
total amount of infiltrating and peripheral CD3+ lymphocytes: in serial sections of the same 
case stained with the two antibodies, 10 high-magnification and non-overlapping fields 
were respectively considered for each marker, paying attention that the observed field of 
the section was the same for the two antibodies (anatomical structures or vessels were 
used as references). In each magnification field, the FoxP3-immunolabeled cells and the 
total of CD3-immunolabeled cells were counted and a percentage was calculated; the 
mean value of the two operators was finally considered. Furthermore, the presence or 
absence of FoxP3+ neoplastic cells with nuclear positivity was also considered. IDO+ 
inflammatory cells were also counted by two operators in 5 HPF (FN 20), choosing “hot 
spots” and avoiding areas near necrosis or ulceration; the mean value was then 
calculated. In this case, the expected labeling was granular and cytoplasmic. The 
presence of IDO+ cells with neoplastic morphology was recorded. 
 
Statistical analysis 
Diagnostic graphics, Shapiro-Wilk and Levene test were used to test assumptions and 
outliers. Mean value of FoxP3+ lymphocytes/HPF (FoxP3+/HPF) and the percentage of 
FoxP3+ lymphocytes were log- and the log(x+1) transformed, respectively. Mitotic count 
was included in the statistical evaluation being one of the most reliable prognostic factors 
in canine melanocytic tumors.3,39,62,64 
We used Univariate Analysis of variance by General Linear Model (GLM) procedure or 
Independent t-test to evaluate associations between IDO+/HPF, FoxP3+/HPF and 
%FoxP3+ with diagnosis, quantity of tumor-infiltrating and peripheral CD3+ T cells 
(classified in 3 categories: mild; moderate and severe) or presence of metastasis. Sidak 
correction was used for multiple comparisons. Chi square and z-test (with Bonferroni 
method) was used for IDO+ and FoxP3+ neoplastic cells, while association between 
quantitative variables was evaluated by using Spearman's correlation coefficient (ρ). The 
GLM was also used to evaluate the association between mitotic count and neoplastic IDO+ 
or FoxP3+ cells (classified in 2 categories: yes or no). We used the Life Table and Kaplan–
Meier methods to calculate disease-free and survival times. The differences of survival 
rate according to diagnosis were evaluated by the log-rank test. We used the Cox 
proportional hazards model (both on all cases and stratifying for diagnosis) to evaluate the 
influence of all the parameters characterizing IDO and FoxP3 on survival. All variables with 
P<0.05 on the univariate analysis were entered into the multivariable model using the 
step-wise backward selection method, and P<0.1 was set for inclusion in the multivariable 
model. The prognostic significance of each variable was expressed as hazard ratio (HR) 
with corresponding 95% confidence intervals (CIs) and P values. The receiver operating 
characteristic (ROC) analysis methodology was used to assess the diagnostic accuracy of 
the parameters (continuous variables) to detect death due to melanoma. On the basis of 
the AUC statistic, the diagnostic test can be non-informative (AUC=0.5), less accurate 
(0.5<AUC≤0.7), moderately accurate (0.7<AUC≤0.9), highly accurate (0.9<AUC<1), or 
perfect (AUC=1).21,66 ROC curves were compared by a critical ratio z.21 Optimal cut-off 
values were determined as points on the curve closest to (0, 1) and by the Youden index. 
Values are expressed as median (Mdn) with interquartile range (IQR) or number and 
percentage. Statistical analysis was performed using SPSS 23.0 (SPSS Inc., Chicago, IL) 
and P≤0.05 was considered statistically significant. 
 
RESULTS 
Sample population 
The signalment of the dogs with melanocytic tumors of this study is summarized in 
Supplemental Table 1. No marked breed predilection was observed, but a higher number 
of Dachshund dogs was present in our study group, compared to the other breeds (8%). 
Among the total population, 43/75 were males (57.3%) of which 5/43 (11.6%) were 
neutered; 28/75 were females (37.3%) of which 8/28 (28.6%) were spayed. In 4 cases 
there was no information about the sex of the dog. No significant difference was found 
between these groups. Median age was 10.4 years. A higher median age was observed 
for oral melanomas (12 years), compared to cutaneous melanomas and melanocytomas 
(11 years and 9 years, respectively) (P<0.001). Twelve cases had evidence of local or 
distant metastasis which was determined in 5/12 (42%) cases via histology, in 3/12 (20%) 
cases via necropsy, in 1/12 (8%) cases via fine needle aspiration of the draining lymph 
node, in 2/12 (17%) cases via clinical assessment and in one case (8%) via radiography 
(lung metastasis). Metastasis was identified in only the draining lymph node in 7/12 cases 
(58.3%), in both a local lymph node and the lung in 1 case (8.3%), and in abdominal 
organs (liver and spleen) in 2/12 (16.7%) cases. Two cases (16.7%), both submitted to 
necropsy, showed systemic neoplastic dissemination. Therapy was limited to surgical 
excision and pain management therapy, except in two cases where chemotherapy was 
attempted. 
 
FoxP3 immunohistochemistry 
In our samples, positive FoxP3 immunolabeling was observed both in the nuclei of small 
mature lymphocytes and, occasionally, also in irregular and large nuclei, often with a 
prominent nucleolus, of neoplastic cells (Table 1). 
FoxP3+ lymphocytes were observed in 24/26 (92%) oral melanomas (Figure 1), 20/23 
(87%) cutaneous melanomas (Figure 2) and in 12/25 (48%) melanocytomas. The number 
of FoxP3+ lymphocytes was positively associated with a worse histological diagnosis 
(P<0.001), with a decreasing quantity from oral melanomas to cutaneous melanomas to 
cutaneous melanocytomas. CD3+ lymphocytes were absent (mucosal melanomas: 2/26, 
8%; cutaneous melanomas: 1/23, 4%; cutaneous melanocytomas: 7/25, 28%), mild 
(mucosal melanomas: 8/26, 31%; cutaneous melanomas: 10/23, 44%; cutaneous 
melanocytomas: 10/25, 40%), moderate (mucosal melanomas: 9/26, 35%; cutaneous 
melanomas: 8/23, 35%; cutaneous melanocytomas: 6/25, 24%), or severe (mucosal 
melanomas: 7/26, 27%; cutaneous melanomas: 4/23, 17%; cutaneous melanocytomas: 
2/25, 8%).  
An association with the histological diagnosis was also observed when the percentage of 
CD3+ cells that were positive for FoxP3 (%FoxP3+) was assessed (P<0.001; Figures 3-4). 
As additional information, the only oral melanocytoma which was excluded from the 
statistical analysis showed no FoxP3+ nuclei. 
FoxP3+/HPF value correlated to %FoxP3+ (P≤0.05), and to the mitotic count (ρ=0.634; 
P<0.001) and was associated with the presence of metastases (P<0.05). The percentage 
of FoxP3+ cells showed a correlation with the mitotic count (ρ=0.551; P<0.001) and an 
association with the presence of metastasis (P=0.012). 
An association with the number of CD3+ lymphocytes was observed for FoxP3+/HPF 
(P<0.001). However, an association with the number of CD3+ lymphocytes was not present 
for %FoxP3+ lymphocytes, even though the P value was bordering statistical significance 
(P=0.056). 
The presence of FoxP3+ neoplastic cells was observed in 16/26 oral melanomas (61%), in 
10/23 cutaneous melanomas (43%) and in none of the cutaneous melanocytomas (0.0%), 
thus being associated with histological diagnosis (P<0.001). In the samples with FoxP3+ 
neoplastic cells, the CD3+ lymphocytic infiltrate was more often severe than mild, while in 
the samples without FoxP3+ neoplastic cells it was usually mild. Mitotic count was higher in 
samples with FoxP3+ neoplastic cells (P<0.001). Also, the absence of FoxP3+ neoplastic 
cells was associated with the lack of detected metastasis (P<0.05). No FoxP3+ neoplastic 
cells were seen in the oral melanocytoma excluded from the study.  
 
IDO immunohistochemistry 
IDO positivity was seen as a cytoplasmic granular labeling in cells interpreted as DCs or 
macrophages, neoplastic cells and rarely in endothelial cells (Figures 5-8). IDO+ cells, 
morphologically interpreted as DCs or macrophages, were observed in 26/26 (100%) oral 
melanomas, 21/23 (91%) cutaneous melanomas and in 19/25 (76%) melanocytomas 
(Table 1). 
Immunohistochemistry revealed an association between the number of IDO+ inflammatory 
cells/HPF and the histological diagnosis (P<0.001); specifically, in oral melanomas their 
number was higher than in cutaneous melanocytomas (P<0.05), while no differences were 
seen between cutaneous melanomas and melanocytomas. The only oral melanocytoma 
showed the presence of 7.2 IDO+/HPF. IDO+ inflammatory cells/HPF showed a positive 
correlation with FoxP3+ lymphocytes/HPF (ρ=0.421; P<0.001) and with %FoxP3+ 
(ρ=0.294; P<0.05); moreover, IDO+ inflammatory cells/HPF were correlated with the 
mitotic count (ρ=0.447; P<0.001), whereas they did not show any association with the total 
number of CD3+ cells or to the presence of metastasis. 
The presence of IDO+ neoplastic cells was observed in 13/26 (50%) oral melanomas, 
10/23 (43%) cutaneous melanomas and in 6/25 (24%) cutaneous melanocytomas. It was 
positively associated with the presence of metastasis (P<0.01), whereas it did not show 
any association with the quantity of CD3+ cells. There were no IDO+ neoplastic cells in the 
oral melanocytoma. 
 
Survival analysis 
Follow-up at the end of the study ranged from 127 to 2013 days, with a median follow-up 
of 821 days. Only two cases had a follow-up <1 year (the dogs died for causes unrelated 
to melanocytic tumors), with 55% of cases being followed for >2 years. 
Considering disease-specific survival (death due to melanoma) as endpoint, the 6-month 
and 1-year estimated survival probabilities were 74±10% and 25±11% for dogs with oral 
melanoma, and 87±9% and 78±11% for those with cutaneous melanoma. The survival 
probability of dogs with melanocytoma was 100+0% at one year. 
Dogs with oral melanoma (median=249 days, IQR=165-355 days) had a lower survival 
probability than those with cutaneous melanoma (median not reached, P=0.002) and 
melanocytoma (median not calculated because all cases were censored, P<0.001). The 
difference was also significant between cutaneous melanoma and melanocytoma 
(P=0.015) 
When considering all tumors together, all the parameters related to IDO and FoxP3 were 
significantly associated with an increased risk of death (Table 2). The stratification 
according to the diagnosis resulted in a loss of statistical significance except for the 
IDO+/HPF in oral melanomas (HR=1.038, 95% CI=1.006–1.070, P=0.020). 
FoxP3+/HPF, FoxP3%, FoxP3+ neoplastic cells, IDO+/HPF, IDO+ neoplastic cells, and 
mitotic count were included in the multivariable model. Multivariable Cox hazard 
regression analysis identified IDO mean (P<0.001) as an independent variable positively 
associated with the risk of death (Table 2). 
 
ROC analysis 
Variables with a P value of <0.05 from the univariate analyses were considered candidate 
variables for predicting tumor-related death and submitted to ROC analysis (i.e., 
FoxP3+/HPF,FoxP3% and IDO+/HPF). Of the 75 animals included in the ROC analysis, 21 
were dead due to melanoma and 54 were alive or dead due to other causes. Results 
showed that FoxP3+/HPF and IDO+/HPF were moderately accurate parameters for 
predicting death while FoxP3% was less accurate (Table 3). However, there were no 
significant differences with the AUC of mitotic counts (z=0.88, z=0.56, and z=1.79 for 
FoxP3+/HPF, IDO+/HPF, and FoxP3% respectively; P>0.05). The optimal cut-offs for 
predicting death were 6.1 for FoxP3+/HPF (Figure 9), 12.5 for FoxP3% (Figure 10) and 
14.7 for IDO+/HPF (Figure 11 and Table 3). 
The risk of death was higher for dogs with FoxP3+/HPF≥6.1 (HR=6.774, 95% CI=2.259–
20.312, P=0.001; Figure 9) and FoxP3%≥12.5 (HR=3.016, 95% CI=1.200–7.583, P=0.019; 
Figure 10). Similarly, IDO+/HPF≥14.7 (HR=4.707, 95% CI=1.890–11.719, P=0.001; Figure 
11) increased the risk of death by 4.7 times. 
 
DISCUSSION 
The role and the profiling of the immune environment is gaining attention in oncology and 
in melanoma research because of the growing evidence of its impact on both prognosis 
and response to immunotherapy.29,28 To our knowledge, studies on canine melanoma 
immunology are few and the use of immunotherapy targeting immune checkpoint 
molecules is still limited to in vitro data.1,5,35,67 This study was intended to provide a first 
overview on the expression of FoxP3 and IDO in primary melanocytic tumors of the dog; 
moreover, it investigates the possible value of these molecules as additional prognostic 
immunohistochemical markers in canine melanoma. 
Results from this study showed that FoxP3+/HPF and FoxP3% were associated with both 
the diagnosis (decreasing quantity from oral melanomas > cutaneous melanomas > 
cutaneous melanocytomas) and the presence of metastasis, suggesting that Tregs might 
play an important role in the establishment of immune tolerance mechanisms, as 
elsewhere suggested, both for dogs and humans.59,40,44 Additionally, in univariate analysis, 
both FoxP3+/HPF and FoxP3% were shown to be prognostic factors in canine melanocytic 
tumors, independently of the diagnosis. FoxP3+/HPF was associated with the quantity of 
CD3+ lymphocytes, but the percentage of FoxP3+ lymphocytes was not. This last result 
points out an inconstant fraction of FoxP3+ cells among the total number of T lymphocytes. 
Thus the prominent Treg infiltration observed in canine oral melanoma could be one of the 
actors contributing to a marked immunosuppressive microenvironment and to the 
activation of immunoescape pathways, thereby contributing to the aggressive clinical 
behavior of these tumors, similar to what is described in human beings.18,38,40,51 However, 
other studies suggest that Tregs can comprise a ‘bad’ subset that contributes to antitumor 
immunity, and a ‘good’ one, with an anti-inflammatory role, which are pivotal in maintaining 
self-tolerance and of benefit to the host.71 Therefore, further investigations are needed to 
better understand the different subsets and the biologic activity of Tregs in canine 
oncology. Another point of concern is that Tregs do not have a specific marker to confirm 
their identity: FoxP3 is a reliable marker in mice but is less reliable in humans. Little 
information is available for the dog, but some recent studies seem to validate FoxP3 as a 
specific marker.70,68,59,15 
Our results showed the expression of FoxP3 by neoplastic cells, as demonstrated by the 
presence of FoxP3+ nuclei in cells with phenotypic features of neoplastic cells. They were 
present only in oral and cutaneous melanoma and their presence was associated with the 
diagnosis, with the quantity of lymphocytes and also with the presence of metastasis; 
moreover, in univariate analysis, the results suggested a prognostic value in canine 
melanocytic tumors. This finding could support the hypothesis proposed by different 
authors that tumor cells could exert a FoxP3-dependent, Treg-like suppressive effect on T 
cells, suggesting that this mimicking of Treg functions could act as an immunosuppressive 
process, further contributing to melanoma cells immunoescape and survival.51,67 
Evaluation of a larger caseload for the co-expression of melanocytic markers and FoxP3 to 
better identify the population of neoplastic cells expressing the transcription factor and 
their role in immunoescape is needed. 
The role of IDO in canine immune regulation is still under examination and few data are 
available in the scientific literature; only one study has investigated the potential use of 
blocking IDO to revert tumor immune suppression and potentiate the effects of radiation 
therapy.10,43,60 To the authors’ knowledge, this is the first study that has investigated the 
expression and the potential biological and prognostic role of this molecule in canine 
melanocytic tumors. Our results showed that the mean number of IDO+ inflammatory 
cells/HPF was associated with the histological diagnosis (decreasing from oral melanomas 
> cutaneous melanomas > cutaneous melanocytomas), but no significant association with 
the presence of T lymphocytes or with metastasis was found. The results of univariate 
analysis identified IDO+ inflammatory cells/HPF as a prognostic marker that was 
associated with a higher hazard of death. Multivariable analysis also selected it as an 
independent factor. Although the low number of cases resulted in the loss of significance 
when stratifying according to tumor type, in oral melanomas IDO+ cells were still 
associated with an increased risk of death. Interestingly, the presence of IDO+ neoplastic 
cells was associated with the presence of metastasis and dogs with IDO+ neoplastic cells 
had a 3 times higher hazard of death compared to those without. In human medicine, the 
expression of IDO in melanoma cells has been observed8,54 and, beyond its role in 
immunosuppression, it has been suggested to be a part of the genetic changes associated 
with malignant transformation.45 From the ROC curve we can infer that optimal cut-offs for 
predicting death were 14.7 for IDO+/HPF, 6.1 for FoxP3+/HPF and 12.5 for FoxP3%, with 
IDO+/HPF being the most specific (76%) and FoxP3+/HPF the most sensitive (81%). 
However, since we performed the analysis on all cases, the values could have been 
affected by the differences of expression in the different tumor types (oral/cutaneous); thus 
the values provided have to be considered indicative and should be confirmed in a wider 
sample size and analyzing cases stratified by diagnosis. Furthermore, due to the presence 
of many dogs lost to follow up or dead for other causes, these results and the results of 
the survival curves must be interpreted with caution and further assessed. 
Our results also indicated a positive correlation between IDO+/HPF and both FoxP3+/HPF 
and FoxP3%. This data seems to confirm the strong interconnection between the two 
molecules; in the last few years it has been demonstrated that IDO can both induce Tregs 
and activate Treg-mediated suppression with different mechanisms and, in turn, Tregs can 
induce IDO.46,73 Our results suggest that the immune profile of the tumor should be 
carefully taken into consideration together with the tumor cell biology, and, if substantiated 
by further studies, could help to define the prognosis in canine melanocytic tumors. 
Cancer immune microenvironment is gaining more and more attention in oncology, since 
evidence of its role in prognosis and response to therapy is accumulating. Immunotherapy 
in the past few years has emerged as a new approach for different types of malignancies, 
including melanoma. Particularly, anti-CTLA-4 therapy demonstrated effectiveness in 
depletion of intratumoral Tregs and its combination with pharmacological IDO inhibition 
even resulted in superior responses.7,58 
The current study suggests, for the first time, a potential role of both FoxP3 and IDO in 
influencing the biological behavior of canine melanocytic tumors, thus the importance that 
an immuno-suppressive tumor microenvironment may play in melanoma progression. Our 
results, including the identification of cut-off values, suggest that FoxP3 and IDO 
immunohistochemistry could help to estimate the prognosis of patients with melanocytic 
tumors.These parameters should be evaluated in association with more commonly used 
prognostic indicators (e.g. mitotic index, nuclear atypia), providing useful information about 
the immune microenvironment of the canine melanocytic tumors. However, this is a 
preliminary retrospective study and the small sample size may be responsible for the loss 
of significance of the IDO and FoxP3 parameters after stratification according to the 
diagnosis. Further studies, with a larger sample population, are advised to confirm the 
potential role of IDO and FoxP3 as prognostic indicators in canine melanocytic tumors and 
to evaluate if these parameters can be useful in predicting canine melanoma response to 
immunotherapeutic approaches. 
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Figure 1-4: Melanoma, dog. Immunohistochemistry for FoxP3 (characterized by nuclear 
immunolabeling) and CD3 (membrane immunolabeling). Figure 1. Case 15. Dense 
infiltrate of FoxP3+ lymphocytes in an oral melanoma. Figure 2. Case 48. FoxP3+ 
lymphocytes in a cutaneous melanoma. Figure 3 and 4. Case 13. Immunohistochemistry 
for FoxP3 (Figure 3) and CD3 (Figure 4) on serial sections of an oral melanoma. 
 
Figure 5-8: Melanoma, dog. Immunohistochemistry for IDO (cytoplasmic granular 
immunolabeling). Figure 5. Case 18. Oral melanoma (asterisk) with peripheral expression 
of IDO in dendritic cells and macrophages (arrowhead). Figure 6. Case 35. Disseminated 
intratumoral IDO+ inflammatory cells in a cutaneous melanoma with metastatic behavior. 
Figure 7. Case 12. Endothelial IDO+ cells in peritumoral stroma (arrows). Figure 8. Case 
51. IDO+ neoplastic cell in a cutaneous melanoma. 
 
Figure 9-11. Survival curves for dogs with melanocytic tumors according to the cut-off 
values of FoxP3 and IDO parameters. Figure 9. Survival curve for FoxP3+ 
lymphocytes/high power field (HPF) (cut-off 6.1; entire sample). Figure 10. Survival curve 
for percentage of CD3+ cells that are FoxP3+ (cut-off 12.5; entire sample). Figure 11. 
Survival curve for IDO+ inflammatory cells/HPF (cut-off 14.7; entire sample).  
 
